JPMorgan raised the firm’s price target on Twist Bioscience to $28 from $25 and keeps an Underweight rating on the shares. The company reported an “encouraging” fiscal Q2 beat, driven by increased Express Genes volume, but there remains a concern around onetime orders due to seasonality and the durability of orders throughout the year, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $55 from $48 at TD Cowen
- Twist Bioscience price target raised to $40 from $39 at Baird
- Twist Bioscience price target raised to $45 from $40 at Barclays
- Twist Bioscience raises FY24 revenue view to $300M-$304M from $288M-$293M
- Twist Bioscience sees Q3 revenue $77M, consensus $73.8M
